Diabetes Management in Cirrhosis

Medication Selection

Insulin is the only evidence-based option for treating diabetes in patients with decompensated cirrhosis, according to the European Association for the Study of the Liver 1, 2
The American Association for the Study of Liver Diseases recommends GLP-1 receptor agonists for use in compensated (Child-Pugh A) cirrhosis 3, 4
SGLT2 inhibitors can be used in Child-Pugh A and B cirrhosis, as suggested by the American Diabetes Association 3, 4
Metformin can be used in compensated cirrhosis with preserved renal function (GFR >30 ml/min), as recommended by the European Association for the Study of the Liver 3, 4

The American Association for the Study of Liver Diseases advises against using HbA1c for diagnosis or monitoring in cirrhosis, especially with impaired liver function (Child-Pugh B-C) 1, 2
Fasting blood glucose levels should not exceed 10 mmol/L to avoid hyperglycemic complications, according to the American Diabetes Association 1, 2
Insulin therapy should be initiated in hospital due to high variations in glucose levels and risks of hypoglycemia, as recommended by the European Association for the Study of the Liver 1, 2

Diabetes affects 30% of cirrhotic patients and increases risk for cirrhosis-related complications and mortality, according to the American Association for the Study of Liver Diseases 1
Poor glycemic control is associated with higher rates of hepatic encephalopathy, as suggested by the European Association for the Study of the Liver 1

Insulin therapy reduces steatosis but effects on liver histology remain unknown, as noted by the American Gastroenterological Association 5, 9
GLP-1 receptor agonists improve steatosis and may slow fibrosis progression, according to the American Diabetes Association 7, 8
SGLT2 inhibitors reduce steatosis by approximately 20% but effects on liver histology remain unknown, as suggested by the American Gastroenterological Association 5, 9

Nutritional status must be considered when managing diabetes in cirrhosis, with emphasis on adequate protein intake (1.2-1.5 g/kg/day) to prevent sarcopenia, as recommended by the American Diabetes Association 3, 4
Alcohol consumption should be completely avoided in patients with advanced fibrosis and cirrhosis, according to the American Association for the Study of Liver Diseases 5, 9